Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2016, Article ID 3432640, 9 pages
http://dx.doi.org/10.1155/2016/3432640
Review Article

Risk and Surveillance of Cancers in Primary Biliary Tract Disease

1Department of Internal Medicine, University of North Dakota, Fargo, ND 58102, USA
2Department of General Internal Medicine, MD Anderson Cancer Center, Houston, TX 77030, USA

Received 21 January 2016; Revised 14 April 2016; Accepted 18 May 2016

Academic Editor: Kerstin Schütte

Copyright © 2016 Valery Hrad et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. M. Boberg, R. W. Chapman, G. M. Hirschfield, A. W. Lohse, M. P. Manns, and E. Schrumpf, “Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue,” Journal of Hepatology, vol. 54, no. 2, pp. 374–385, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. A. J. Czaja, “Diagnosis and management of the overlap syndromes of autoimmune hepatitis,” Canadian Journal of Gastroenterology, vol. 27, no. 7, pp. 417–423, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Kaya, P. Angulo, and K. D. Lindor, “Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system,” Journal of Hepatology, vol. 33, no. 4, pp. 537–542, 2000. View at Publisher · View at Google Scholar · View at Scopus
  4. E. M. M. Kuiper, P. E. Zondervan, and H. R. van Buuren, “Paris criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome,” Clinical Gastroenterology and Hepatology, vol. 8, no. 6, pp. 530–534, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Chapman, J. Fevery, A. Kalloo et al., “Diagnosis and management of primary sclerosing cholangitis,” Hepatology, vol. 51, no. 2, pp. 660–678, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. P. Angulo and K. D. Lindor, “Primary sclerosing cholangitis,” Hepatology, vol. 30, no. 1, pp. 325–332, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. J.-N. Vauthey and L. H. Blumgart, “Recent advances in the management of cholangiocarcinomas,” Seminars in Liver Disease, vol. 14, no. 2, pp. 109–114, 1994. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Patel, “Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States,” Hepatology, vol. 33, no. 6, pp. 1353–1357, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. H. Shaib, J. A. Davila, K. McGlynn, and H. B. El-Serag, “Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?” Journal of Hepatology, vol. 40, no. 3, pp. 472–477, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Bergquist, A. Ekbom, R. Olsson et al., “Hepatic and extrahepatic malignancies in primary sclerosing cholangitis,” Journal of Hepatology, vol. 36, no. 3, pp. 321–327, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Rudolph, D. Gotthardt, P. Kloeters-Plachky, D. Rost, H. Kulaksiz, and A. Stiehl, “In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival,” Journal of Hepatology, vol. 53, no. 2, pp. 313–317, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Jaiswal, N. F. LaRusso, L. J. Burgart, and G. J. Gores, “Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism,” Cancer Research, vol. 60, no. 1, pp. 184–190, 2000. View at Google Scholar · View at Scopus
  13. W. R. Wu, X. D. Shi, R. Zhang et al., “Clinicopathological significance of aberrant Notch receptors in intrahepatic cholangiocarcinoma,” International Journal of Clinical and Experimental Pathology, vol. 7, no. 6, pp. 3272–3279, 2014. View at Google Scholar
  14. M. El Khatib, P. Bozko, V. Palagani, N. P. Malek, L. Wilkens, and R. R. Plentz, “Activation of Notch signaling is required for cholangiocarcinoma progression and is enhanced by inactivation of p53 in vivo,” PloS one, vol. 8, no. 10, Article ID e77433, 2013. View at Google Scholar · View at Scopus
  15. R. V. Guest, L. Boulter, T. J. Kendall et al., “Cell lineage tracing reveals a biliary origin of intrahepatic cholangiocarcinoma,” Cancer Research, vol. 74, no. 4, pp. 1005–1010, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. W.-R. Wu, R. Zhang, X.-D. Shi et al., “Notch1 is overexpressed in human intrahepatic cholangiocarcinoma and is associated with its proliferation, invasiveness and sensitivity to 5-fluorouracil in vitro,” Oncology Reports, vol. 31, no. 6, pp. 2515–2524, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. M. T. Dill, L. Tornillo, T. Fritzius et al., “Constitutive Notch2 signaling induces hepatic tumors in mice,” Hepatology, vol. 57, no. 4, pp. 1607–1619, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. E. Melum, T. H. Karlsen, E. Schrumpf et al., “Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphisms,” Hepatology, vol. 47, no. 1, pp. 90–96, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. S. E. Kerr, E. G. Barr Fritcher, M. B. Campion et al., “Biliary dysplasia in primary sclerosing cholangitis harbors cytogenetic abnormalities similar to cholangiocarcinoma,” Human Pathology, vol. 45, no. 9, pp. 1797–1804, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. N. Razumilava, G. J. Gores, and K. D. Lindor, “Cancer surveillance in patients with primary sclerosing cholangitis,” Hepatology, vol. 54, no. 5, pp. 1842–1852, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Serrablo and L. Tejedor, “Outcome of surgical resection in Klatskin tumors,” World Journal of Gastrointestinal Oncology, vol. 5, no. 7, pp. 147–158, 2013. View at Publisher · View at Google Scholar
  22. J. E. Eaton, J. A. Talwalkar, K. N. Lazaridis, G. J. Gores, and K. D. Lindor, “Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management,” Gastroenterology, vol. 145, no. 3, pp. 521–536, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. G. Morris-Stiff, C. Bhati, S. Olliff et al., “Cholangiocarcinoma complicating primary sclerosing cholangitis: a 24-year experience,” Digestive Surgery, vol. 25, no. 2, pp. 126–132, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. K. M. Boberg, A. Bergquist, S. Mitchell et al., “Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation,” Scandinavian Journal of Gastroenterology, vol. 37, no. 10, pp. 1205–1211, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. P. Manninen, A.-L. Karvonen, J. Laukkarinen, P. Aitola, H. Huhtala, and P. Collin, “Colorectal cancer and cholangiocarcinoma in patients with primary sclerosing cholangitis and inflammatory bowel disease,” Scandinavian Journal of Gastroenterology, vol. 50, no. 4, pp. 423–428, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Wee, J. Ludwig, R. J. Coffey Jr., N. F. LaRusso, and R. H. Wiesner, “Hepatobiliary carcinoma associated with primary sclerosing cholangitis and chronic ulcerative colitis,” Human Pathology, vol. 16, no. 7, pp. 719–726, 1985. View at Publisher · View at Google Scholar · View at Scopus
  27. U. Broomé, R. Olsson, L. Lööf et al., “Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis,” Gut, vol. 38, no. 4, pp. 610–615, 1996. View at Publisher · View at Google Scholar · View at Scopus
  28. N. Chalasani, A. Baluyut, A. Ismail et al., “Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study,” Hepatology, vol. 31, no. 1, pp. 7–11, 2000. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Levy, J. Lymp, P. Angulo, G. J. Gores, N. Larusso, and K. D. Lindor, “The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis,” Digestive Diseases and Sciences, vol. 50, no. 9, pp. 1734–1740, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. P. Charatcharoenwitthaya, F. B. Enders, K. C. Halling, and K. D. Lindor, “Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis,” Hepatology, vol. 48, no. 4, pp. 1106–1117, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. A. C. Berger, M. Garcia Jr., J. P. Hoffman et al., “Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704,” Journal of Clinical Oncology, vol. 26, no. 36, pp. 5918–5922, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. Technology Assessment Committe, A. Barkun, J. Liu et al., “Update on endoscopic tissue sampling devices,” Gastrointestinal Endoscopy, vol. 63, no. 6, pp. 741–745, 2006. View at Publisher · View at Google Scholar
  33. K. Modha and U. Navaneethan, “Diagnosis and management of primary sclerosing cholangitis-perspectives from a therapeutic endoscopist,” World Journal of Hepatology, vol. 7, no. 5, pp. 799–805, 2015. View at Publisher · View at Google Scholar · View at Scopus
  34. Y. Ishii, T. Sasaki, M. Serikawa et al., “Characteristic features of cholangiocarcinoma complicating primary sclerosing cholangitis,” Hepatogastroenterology, vol. 61, no. 131, pp. 567–573, 2014. View at Google Scholar · View at Scopus
  35. G. Trikudanathan, U. Navaneethan, B. Njei, J. J. Vargo, and M. A. Parsi, “Diagnostic yield of bile duct brushings for cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis,” Gastrointestinal Endoscopy, vol. 79, no. 5, pp. 783–789, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. U. Navaneethan, B. Njei, P. G. K. Venkatesh, J. J. Vargo, and M. A. Parsi, “Fluorescence in situ hybridization for diagnosis of cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis,” Gastrointestinal Endoscopy, vol. 79, no. 6, pp. 943–950.e3, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Bergquist, B. Tribukait, H. Glaumann, and U. Broomé, “Can DNA cytometry be used for evaluation of malignancy and premalignancy in bile duct strictures in primary sclerosing cholangitis?” Journal of Hepatology, vol. 33, no. 6, pp. 873–877, 2000. View at Publisher · View at Google Scholar · View at Scopus
  38. J. E. Eaton, E. G. Barr Fritcher, G. J. Gores et al., “Biliary multifocal chromosomal polysomy and cholangiocarcinoma in primary sclerosing cholangitis,” The American Journal of Gastroenterology, vol. 110, no. 2, pp. 299–309, 2015. View at Publisher · View at Google Scholar
  39. K. Andresen, K. M. Boberg, H. M. Vedeld et al., “Four DNA methylation biomarkers in biliary brush samples accurately identify the presence of cholangiocarcinoma,” Hepatology, vol. 61, no. 5, pp. 1651–1659, 2015. View at Publisher · View at Google Scholar · View at Scopus
  40. U. Navaneethan, M. A. Parsi, D. Lourdusamy et al., “Volatile organic compounds in urine for noninvasive diagnosis of malignant biliary strictures: a pilot study,” Digestive Diseases and Sciences, vol. 60, no. 7, pp. 2150–2157, 2015. View at Publisher · View at Google Scholar · View at Scopus
  41. T. Voigtländer, S. K. Gupta, S. Thum et al., “MicroRNAs in serum and bile of patients with primary sclerosing cholangitis and/or cholangiocarcinoma,” PLOS ONE, vol. 10, no. 10, article e0139305, 2015. View at Publisher · View at Google Scholar
  42. T. O. Lankisch, J. Metzger, A. A. Negm et al., “Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis,” Hepatology, vol. 53, no. 3, pp. 875–884, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. M.-M. Xu and A. Sethi, “Diagnosing biliary malignancy,” Gastrointestinal Endoscopy Clinics of North America, vol. 25, no. 4, pp. 677–690, 2015. View at Publisher · View at Google Scholar
  44. Y. K. Chen, M. A. Parsi, K. F. Binmoeller et al., “Single-operator cholangioscopy in patients requiring evaluation of bile duct disease or therapy of biliary stones (with videos),” Gastrointestinal Endoscopy, vol. 74, no. 4, pp. 805–814, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. E. Kalaitzakis, G. J. Webster, K. W. Oppong et al., “Diagnostic and therapeutic utility of single-operator peroral cholangioscopy for indeterminate biliary lesions and bile duct stones,” European Journal of Gastroenterology and Hepatology, vol. 24, no. 6, pp. 656–664, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. R. J. Shah, “Cholangiocarcionoma and primary sclerosing cholangitis: the answer lies within,” Gastrointestinal Endoscopy, vol. 79, no. 5, pp. 780–782, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. E. Kalaitzakis, R. Sturgess, H. Kaltsidis et al., “Diagnostic utility of single-user peroral cholangioscopy in sclerosing cholangitis,” Scandinavian Journal of Gastroenterology, vol. 49, no. 10, pp. 1237–1244, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. N. Azeem, C. J. Gostout, M. Knipschield, and T. H. Baron, “Cholangioscopy with narrow-band imaging in patients with primary sclerosing cholangitis undergoing ERCP,” Gastrointestinal Endoscopy, vol. 79, no. 5, pp. 773–779e2, 2014. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Heif, R. D. Yen, and R. J. Shah, “ERCP with probe-based confocal laser endomicroscopy for the evaluation of dominant biliary stenoses in primary sclerosing cholangitis patients,” Digestive Diseases and Sciences, vol. 58, no. 7, pp. 2068–2074, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Meining, R. J. Shah, A. Slivka et al., “Classification of probe-based confocal laser endomicroscopy findings in pancreaticobiliary strictures,” Endoscopy, vol. 44, no. 3, pp. 251–257, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. A. Meining, Y. K. Chen, D. Pleskow et al., “Direct visualization of indeterminate pancreaticobiliary strictures with probe-based confocal laser endomicroscopy: a multicenter experience,” Gastrointestinal Endoscopy, vol. 74, no. 5, pp. 961–968, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2016,” CA: A Cancer Journal for Clinicians, vol. 66, no. 1, pp. 7–30, 2016. View at Publisher · View at Google Scholar
  53. U. Broomé, R. Löfberg, B. Veress, and L. S. Eriksson, “Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential,” Hepatology, vol. 22, no. 5, pp. 1404–1408, 1995. View at Publisher · View at Google Scholar · View at Scopus
  54. A. N. Ananthakrishnan, A. Cagan, V. S. Gainer et al., “Mortality and extraintestinal cancers in patients with primary sclerosing cholangitis and inflammatory bowel disease,” Journal of Crohn's and Colitis, vol. 8, no. 9, pp. 956–963, 2014. View at Publisher · View at Google Scholar · View at Scopus
  55. R. M. Soetikno, O. S. Lin, P. A. Heidenreich, H. S. Young, and M. O. Blackstone, “Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis,” Gastrointestinal Endoscopy, vol. 56, no. 1, pp. 48–54, 2002. View at Publisher · View at Google Scholar · View at Scopus
  56. E. V. Loftus Jr., G. C. Harewood, C. G. Loftus et al., “PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis,” Gut, vol. 54, no. 1, pp. 91–96, 2005. View at Publisher · View at Google Scholar · View at Scopus
  57. H. Jayaram, J. Satsangi, and R. W. Chapman, “Increased colorectal neoplasia in chronic ulcerative colitis complicated by primary sclerosing cholangitis: fact or fiction?” Gut, vol. 48, no. 3, pp. 430–434, 2001. View at Publisher · View at Google Scholar · View at Scopus
  58. F. P. Vleggaar, M. W. M. D. Lutgens, and M. M. H. Claessen, “Review article: the relevance of surveillance endoscopy in long-lasting inflammatory bowel disease,” Alimentary Pharmacology and Therapeutics, vol. 26, supplement 2, pp. 47–52, 2007. View at Publisher · View at Google Scholar · View at Scopus
  59. T. Kitiyakara and R. W. Chapman, “Chemoprevention and screening in primary sclerosing cholangitis,” Postgraduate Medical Journal, vol. 84, no. 991, pp. 228–237, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. G. G. Kaplan, S. J. Heitman, R. J. Hilsden et al., “Population-based analysis of practices and costs of surveillance for colonic dysplasia in patients with primary sclerosing cholangitis and colitis,” Inflammatory Bowel Diseases, vol. 13, no. 11, pp. 1401–1407, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. M. T. Carriaga and D. E. Henson, “Liver, gallbladder, extrahepatic bile ducts, and pancreas,” Cancer, vol. 75, supplement 1, pp. 171–190, 1995. View at Publisher · View at Google Scholar · View at Scopus
  62. D. C. Buckles, K. D. Lindor, N. F. LaRusso, L. M. Petrovic, and G. J. Gores, “In primary sclerosing cholangitis, gallbladder polyps are frequently malignant,” The American Journal of Gastroenterology, vol. 97, no. 5, pp. 1138–1142, 2002. View at Publisher · View at Google Scholar · View at Scopus
  63. R. Zenouzi, T. J. Weismüller, P. Hübener et al., “Low risk of hepatocellular carcinoma in patients with primary sclerosing cholangitis with cirrhosis,” Clinical Gastroenterology and Hepatology, vol. 12, no. 10, pp. 1733–1738, 2014. View at Publisher · View at Google Scholar · View at Scopus
  64. M. I. Prince, A. Chetwynd, P. Diggle, M. Jarner, J. V. Metcalf, and O. F. W. James, “The geographical distribution of primary biliary cirrhosis in a well-defined cohort,” Hepatology, vol. 34, no. 6, pp. 1083–1088, 2001. View at Publisher · View at Google Scholar · View at Scopus
  65. R. J. Q. McNally, P. W. James, S. Ducker, P. D. Norman, and O. F. W. James, “No rise in incidence but geographical heterogeneity in the occurrence of primary biliary cirrhosis in north east england,” American Journal of Epidemiology, vol. 179, no. 4, pp. 492–498, 2014. View at Publisher · View at Google Scholar · View at Scopus
  66. C. R. Muirhead, O. F. W. James, S. J. Ducker, and R. J. Q. McNally, “Does primary biliary cirrhosis cluster in time?” Spatial and Spatio-temporal Epidemiology, vol. 14-15, pp. 1–8, 2015. View at Publisher · View at Google Scholar · View at Scopus
  67. A. F. Gulamhusein, B. D. Juran, and K. N. Lazaridis, “Genome-wide association studies in primary biliary cirrhosis,” Seminars in Liver Disease, vol. 35, no. 4, pp. 392–401, 2015. View at Publisher · View at Google Scholar
  68. J. Underbill, P. Donaldson, G. Bray, D. Doherty, B. Portmann, and R. Williams, “Susceptibility to primary biliary cirrhosis is associated with the HLA-DR8-DQB1 0402 haplotype,” Hepatology, vol. 16, no. 6, pp. 1404–1408, 1992. View at Publisher · View at Google Scholar · View at Scopus
  69. J. A. Underhill, P. T. Donaldson, D. G. Doherty, K. Manabe, and R. Williams, “HLA DPB polymorphism in primary sclerosing cholangitis and primary biliary cirrhosis,” Hepatology, vol. 21, no. 4, pp. 959–962, 1995. View at Publisher · View at Google Scholar · View at Scopus
  70. L. Wang, Y. Sun, Z. Zhang et al., “CXCR5+ CD4+ T follicular helper cells participate in the pathogenesis of primary biliary cirrhosis,” Hepatology, vol. 61, no. 2, pp. 627–638, 2015. View at Publisher · View at Google Scholar · View at Scopus
  71. F. Limongi, “Th1 cytokines and chemokines in primary biliary cirrhosis,” Clinical Therapeutics, vol. 166, no. 2, pp. e122–e125, 2015. View at Google Scholar
  72. V. Thomas, B. Chipchase, L. Rippon, and P. McArdle, “The application of mental health legislation in younger children,” BJPsych Bulletin, vol. 39, no. 6, pp. 302–304, 2015. View at Publisher · View at Google Scholar
  73. M. Deutsch, G. V. Papatheodoridis, A. Tzakou, and S. J. Hadziyannis, “Risk of hepatocellular carcinoma and extrahepatic malignancies in primary biliary cirrhosis,” European Journal of Gastroenterology and Hepatology, vol. 20, no. 1, pp. 5–9, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. A. Cavazza, L. Caballerí, A. Floreani et al., “Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers,” Hepatology, vol. 50, no. 4, pp. 1162–1168, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. S. Nair, A. Mason, J. Eason, G. Loss, and R. P. Perrillo, “Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?” Hepatology, vol. 36, no. 1, pp. 150–155, 2002. View at Publisher · View at Google Scholar · View at Scopus
  76. K. Boonstra, R. Bokelaar, P. H. Stadhouders et al., “Increased cancer risk in a large population-based cohort of patients with primary biliary cirrhosis: follow-up for up to 36 years,” Hepatology International, vol. 8, no. 2, pp. 266–274, 2014. View at Publisher · View at Google Scholar · View at Scopus
  77. Y. Liang, Z. Yang, and R. Zhong, “Primary biliary cirrhosis and cancer risk: a systematic review and meta-analysis,” Hepatology, vol. 56, no. 4, pp. 1409–1417, 2012. View at Publisher · View at Google Scholar · View at Scopus
  78. P. J. Trivedi, W. J. Lammers, H. R. van Buuren et al., “Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study,” Gut, vol. 65, no. 2, pp. 321–329, 2016. View at Publisher · View at Google Scholar
  79. B. M. Goudie, A. D. Burt, P. Boyle et al., “Breast cancer in women with primary biliary cirrhosis,” British Medical Journal, vol. 291, no. 6509, pp. 1597–1598, 1985. View at Publisher · View at Google Scholar · View at Scopus
  80. A. M. Wolke, F. Schaffner, B. Kapelman, and H. S. Sacks, “Malignancy in primary biliary cirrhosis. High incidence of breast cancer in affected women,” The American Journal of Medicine, vol. 76, no. 6, pp. 1075–1078, 1984. View at Publisher · View at Google Scholar · View at Scopus
  81. A. Floreani, M. R. Biagini, M. Chiaramonte, S. Milani, C. Surrenti, and R. Naccarato, “Incidence of hepatic and extra-hepatic malignancies in primary biliary cirrhosis (PBC),” Italian Journal of Gastroenterology, vol. 25, no. 9, pp. 473–476, 1993. View at Google Scholar · View at Scopus
  82. L. Lööf, H.-O. Adami, P. Sparén et al., “Cancer risk in primary biliary cirrhosis: a population-based study from Sweden,” Hepatology, vol. 20, no. 1, part 1, pp. 101–104, 1994. View at Publisher · View at Google Scholar · View at Scopus
  83. E. Kokue and Y. Takahashi, “Protective effect of sodium polyacrylate on induced duodenal ulceration in guinea pigs,” Japanese Journal of Pharmacology, vol. 26, no. 6, pp. 760–762, 1976. View at Publisher · View at Google Scholar · View at Scopus
  84. C. Frenzel, J. Herkel, S. Lüth, P. R. Galle, C. Schramm, and A. W. Lohse, “Evaluation of F-actin ELISA for the diagnosis of autoimmune hepatitis,” The American Journal of Gastroenterology, vol. 101, no. 12, pp. 2731–2736, 2006. View at Publisher · View at Google Scholar · View at Scopus
  85. M. P. Manns, A. J. Czaja, J. D. Gorham et al., “Diagnosis and management of autoimmune hepatitis,” Hepatology, vol. 51, no. 6, pp. 2193–2213, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. J. N. Rubin and H. S. Te, “Refractory autoimmune hepatitis: beyond standard therapy,” Digestive Diseases and Sciences, vol. 61, no. 6, pp. 1757–1762, 2016. View at Publisher · View at Google Scholar
  87. K. W. Burak, M. G. Swain, T. Santodomingo-Garzon et al., “Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy,” Canadian Journal of Gastroenterology and Hepatology, vol. 27, no. 5, pp. 273–280, 2013. View at Publisher · View at Google Scholar
  88. M. Werner, S. Almer, H. Prytz et al., “Hepatic and extrahepatic malignancies in autoimmune hepatitis. A long-term follow-up in 473 Swedish patients,” Journal of Hepatology, vol. 50, no. 2, pp. 388–393, 2009. View at Publisher · View at Google Scholar · View at Scopus
  89. K. K. Wang, A. J. Czaja, S. J. Beaver, and V. L. W. Go, “Extrahepatic malignancy following long-term immunosuppressive therapy of severe hepatitis B surface antigen-negative chronic active hepatitis,” Hepatology, vol. 10, no. 1, pp. 39–43, 1989. View at Publisher · View at Google Scholar · View at Scopus
  90. J. Leung, L. Dowling, I. Obadan et al., “Risk of non-melanoma skin cancer in autoimmune hepatitis,” Digestive Diseases and Sciences, vol. 55, no. 11, pp. 3218–3223, 2010. View at Publisher · View at Google Scholar · View at Scopus
  91. L. Váróczy, L. Gergely, M. Zeher, G. Szegedi, and Á. Illés, “Malignant lymphoma-associated autoimmune diseases—a descriptive epidemiological study,” Rheumatology International, vol. 22, no. 6, pp. 233–237, 2002. View at Publisher · View at Google Scholar
  92. C. E. M. De Block, I. H. De Leeuw, P. A. Pelckmans et al., “Autoimmune hepatitis, autoimmune gastritis, and gastric carcinoid in a type 1 diabetic patient: a case report,” Journal of Diabetes and its Complications, vol. 14, no. 2, pp. 116–120, 2000. View at Publisher · View at Google Scholar · View at Scopus
  93. H. Kondo, J. Watanabe, and H. Iwasaki, “T-large granular lymphocyte leukemia accompanied by an increase of natural killer cells (CD3-) and associated with ulcerative colitis and autoimmune hepatitis,” Leukemia and Lymphoma, vol. 41, no. 1-2, pp. 207–212, 2001. View at Publisher · View at Google Scholar · View at Scopus
  94. C. G. Begley, I. R. Mackay, and P. S. Bhathal, “Another immune-mediated disease associated with hairy cell leukemia: chronic active hepatitis,” Acta Haematologica, vol. 73, no. 2, pp. 104–105, 1985. View at Google Scholar · View at Scopus
  95. K. K. Wang and A. J. Czaja, “Hepatocellular carcinoma in corticosteroid-treated severe autoimmune chronic active hepatitis,” Hepatology, vol. 8, no. 6, pp. 1679–1683, 1988. View at Publisher · View at Google Scholar · View at Scopus
  96. A. J. Montano-Loza, H. A. Carpenter, and A. J. Czaja, “Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis,” The American Journal of Gastroenterology, vol. 103, no. 8, pp. 1944–1951, 2008. View at Publisher · View at Google Scholar · View at Scopus
  97. A. D. Yeoman, T. Al-Chalabi, J. B. Karani et al., “Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: implications for follow-up and screening,” Hepatology, vol. 48, no. 3, pp. 863–870, 2008. View at Publisher · View at Google Scholar · View at Scopus
  98. S. Z. Park, D. M. Nagorney, and A. J. Czaja, “Hepatocellular carcinoma in autoimmune hepatitis,” Digestive Diseases and Sciences, vol. 45, no. 10, pp. 1944–1948, 2000. View at Publisher · View at Google Scholar · View at Scopus
  99. R. J. Wong, R. Gish, T. Frederick, N. Bzowej, and C. Frenette, “Development of hepatocellular carcinoma in autoimmune hepatitis patients: a case series,” Digestive Diseases and Sciences, vol. 56, no. 2, pp. 578–585, 2011. View at Publisher · View at Google Scholar · View at Scopus
  100. Y. Miyake, Y. Iwasaki, R. Terada et al., “Persistent elevation of serum alanine aminotransferase levels leads to poor survival and hepatocellular carcinoma development in type 1 autoimmune hepatitis,” Alimentary Pharmacology and Therapeutics, vol. 24, no. 8, pp. 1197–1205, 2006. View at Publisher · View at Google Scholar · View at Scopus
  101. A. Danielsson Borssén, S. Almer, H. Prytz et al., “Hepatocellular and extrahepatic cancer in patients with autoimmune hepatitis—a long-term follow-up study in 634 Swedish patients,” Scandinavian Journal of Gastroenterology, vol. 50, no. 2, pp. 217–223, 2015. View at Publisher · View at Google Scholar · View at Scopus
  102. N. Tapuria, C. K. Sinha, N. G. Michael, and P. W. Fisher, “Haematogenous metastasis to ascending colon in a patient with hepatocellular carcinoma and autoimmune hepatitis,” European Journal of Gastroenterology and Hepatology, vol. 19, no. 7, pp. 607–609, 2007. View at Publisher · View at Google Scholar · View at Scopus
  103. Ç. Arslan, S. Kiliçkap, and Ş. Yalçin, “Gastric cancer after cadaveric liver transplantation in a patient with autoimmune hepatitis: a case report and review of the literature,” Turkish Journal of Gastroenterology, vol. 22, no. 1, pp. 73–76, 2011. View at Publisher · View at Google Scholar · View at Scopus
  104. P. Milkiewicz, D. Mutimer, S. G. Hubscher, and E. Elias, “Autoimmune liver disease in patients with neoplastic diseases,” European Journal of Gastroenterology and Hepatology, vol. 11, no. 5, pp. 569–573, 1999. View at Publisher · View at Google Scholar · View at Scopus